WHO Drug Study for Buruli Ulcer - Comparison of SR8 and CR8

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

310

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

December 31, 2017

Study Completion Date

January 31, 2018

Conditions
Mycobacterium Ulcerans Infection
Interventions
DRUG

Clarithromycin Extended Release

oral administration of Clarithromycin extended release

DRUG

Streptomycin intramuscular injection

daily intramuscular drug injection

Trial Locations (5)

Unknown

Pobè Treatment Center, Pobè

Agogo Presbyterian Hospital, Agogo

Dunkwa Government Hospital, Dunkwa-on-Offin

Nkawie-Toase Government Hospital, Nkawie Panyin

Tepa Government Hosital, Tepa

All Listed Sponsors
collaborator

University of Groningen

OTHER

collaborator

Faculté de Médecine P&M Curie, Paris-6 - Site Pitié-Salpêtrière, France

UNKNOWN

collaborator

Drugs for Neglected Diseases

OTHER

collaborator

World Alliance for Wound and Lymphoedema Care, Switzerland

UNKNOWN

collaborator

Inserm U892/CNRS 699 bactériologie, Université CHU;Angers- IRIS France

UNKNOWN

collaborator

Institute of Tropical Medicine, Antwerp, Belgium

UNKNOWN

collaborator

National Buruli ulcer Control Programme, Ghana Health Service, Accra, Ghana

UNKNOWN

collaborator

School of Med Sciences, Kwame Nkrumah Univ of Sci & Techn, Kumasi, Ghana

UNKNOWN

collaborator

Komfo Anokye Teaching Hospital

OTHER

collaborator

Kumasi Center for Collaborative Research into Tropical Medicine, Kumasi, Ghana

UNKNOWN

collaborator

Plastic Surgery and Burns Centre, Korle-Bu Teaching Hospital, Accra, Ghana

UNKNOWN

collaborator

University of Ghana

OTHER

collaborator

Noguchi Memorial Institute of Medical Research, Accra, Ghana

UNKNOWN

collaborator

Program Nat de Lutte contre la Lèpre et l'UB;Ulcère de Buruli, Cotonou, Benin

UNKNOWN

lead

University Medical Center Groningen

OTHER

NCT01659437 - WHO Drug Study for Buruli Ulcer - Comparison of SR8 and CR8 | Biotech Hunter | Biotech Hunter